ImmunityBio, Inc. (IBRX)

NASDAQ

$2.21

-$0.15 (6.57%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$2.15$2.42

Open $2.42

52 Week Range

$1.83$4.27

Previous Close $2.36

Market Cap2.17B

Volume14.90M

Avg Volume9.84M

P/E (TTM)-5.99

EPS (TTM)$-0.37

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for ImmunityBio, Inc.

DEC122025

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

Source: Business Wire•4 days ago

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA® (nogapendekin ...

NOV132025

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

Source: Business Wire•32 days ago

CULVER CITY, Calif.--(BUSINESS WIRE)--A new U.S. survey conducted by The Harris Poll on behalf of ImmunityBio, Inc. (NASDAQ: IBRX) reveals that many people living with non-muscle invasive bladder cancer (NMIBC) feel left out of critical treatment con...

NOV42025

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Source: Business Wire•41 days ago

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30, 2025. In the third quarter of 2025, ImmunityBio ...